U.S. FDA panel votes cannot ignore unsuccessful trial data on Biogen Alzheimer's drug

Mitchell Daily Republic

Nov 6, 2020

They also voted that an earlier-stage study does not offer supportive evidence of Biogen's application for the drug, aducanumab. That vote was 7-0 with 4 "uncertain" votes.